Pharming Group N.V. Overview
Pro stress-test →Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases, commercializing and developing a portfolio of innovative medicines including small molecules and biologics. The company is headquartered in Leiden, the Netherlands, and serves patients in over 30 markets globally.
Strategic Profile
Pro stress-test →Pharming's promotion to the AMX mid-cap index in September 2025 reflects the company's strong growth momentum. The company is focused on executing significant commercial and pipeline catalysts to develop into a leading global rare disease company.
Competitive Landscape
Pro stress-test →Pharming's lead commercial product RUCONEST is a recombinant human C1-esterase inhibitor for hereditary angioedema treatment. The company competes in the rare disease space with focused portfolios targeting unmet needs in immunodeficiency and complement-mediated disorders, competing against larger pharma and specialty biotech firms with similar disease focus.
Industry Context
Pharming Group N.V. operates in Biopharmaceuticals - Rare Diseases.
Key facts
Founded: 1988 · Headquarters: Leiden, Netherlands